<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>10 Esophagectomy Ward | GI Surgical Oncology</title>
  <meta name="description" content="Orientation Manual for GI Surgical Oncology Service" />
  <meta name="generator" content="bookdown 0.24 and GitBook 2.6.7" />

  <meta property="og:title" content="10 Esophagectomy Ward | GI Surgical Oncology" />
  <meta property="og:type" content="book" />
  
  
  <meta property="og:description" content="Orientation Manual for GI Surgical Oncology Service" />
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="10 Esophagectomy Ward | GI Surgical Oncology" />
  
  <meta name="twitter:description" content="Orientation Manual for GI Surgical Oncology Service" />
  




  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="esophagectomy-postop.html"/>
<link rel="next" href="colorectal-cases---hill.html"/>
<script src="libs/header-attrs-2.11/header-attrs.js"></script>
<script src="libs/jquery-3.5.1/jquery-3.5.1.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="libs/anchor-sections-1.0.1/anchor-sections.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.0.1/anchor-sections.js"></script>



<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

<link rel="stylesheet" href="style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li>GI Surgical Oncology</li>

<li class="divider"></li>
<li class="chapter" data-level="1" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i><b>1</b> Overview</a>
<ul>
<li class="chapter" data-level="1.1" data-path="index.html"><a href="index.html#absences"><i class="fa fa-check"></i><b>1.1</b> Absences</a></li>
<li class="chapter" data-level="1.2" data-path="index.html"><a href="index.html#communication"><i class="fa fa-check"></i><b>1.2</b> Communication</a></li>
<li class="chapter" data-level="1.3" data-path="index.html"><a href="index.html#inpatients"><i class="fa fa-check"></i><b>1.3</b> Inpatients</a></li>
<li class="chapter" data-level="1.4" data-path="index.html"><a href="index.html#er-admits"><i class="fa fa-check"></i><b>1.4</b> ER admits</a></li>
<li class="chapter" data-level="1.5" data-path="index.html"><a href="index.html#medical-records"><i class="fa fa-check"></i><b>1.5</b> Medical Records</a></li>
<li class="chapter" data-level="1.6" data-path="index.html"><a href="index.html#operative-logs"><i class="fa fa-check"></i><b>1.6</b> Operative Logs</a></li>
<li class="chapter" data-level="1.7" data-path="index.html"><a href="index.html#case-assignment"><i class="fa fa-check"></i><b>1.7</b> Case Assignment</a></li>
<li class="chapter" data-level="1.8" data-path="index.html"><a href="index.html#clinic"><i class="fa fa-check"></i><b>1.8</b> Clinic</a></li>
<li class="chapter" data-level="1.9" data-path="index.html"><a href="index.html#work-hours"><i class="fa fa-check"></i><b>1.9</b> Work Hours</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="inpatient.html"><a href="inpatient.html"><i class="fa fa-check"></i><b>2</b> Inpatient</a>
<ul>
<li class="chapter" data-level="2.1" data-path="inpatient.html"><a href="inpatient.html#admissions"><i class="fa fa-check"></i><b>2.1</b> Admissions</a></li>
<li class="chapter" data-level="2.2" data-path="inpatient.html"><a href="inpatient.html#rounds"><i class="fa fa-check"></i><b>2.2</b> Rounds</a></li>
<li class="chapter" data-level="2.3" data-path="inpatient.html"><a href="inpatient.html#resident-halo-teams"><i class="fa fa-check"></i><b>2.3</b> Resident Halo teams:</a></li>
<li class="chapter" data-level="2.4" data-path="inpatient.html"><a href="inpatient.html#attending-halo-teams"><i class="fa fa-check"></i><b>2.4</b> Attending Halo teams:</a></li>
<li class="chapter" data-level="2.5" data-path="inpatient.html"><a href="inpatient.html#consults"><i class="fa fa-check"></i><b>2.5</b> Consults</a></li>
<li class="chapter" data-level="2.6" data-path="inpatient.html"><a href="inpatient.html#conferences"><i class="fa fa-check"></i><b>2.6</b> Conferences</a></li>
</ul></li>
<li class="chapter" data-level="3" data-path="rounds-1.html"><a href="rounds-1.html"><i class="fa fa-check"></i><b>3</b> Rounds</a></li>
<li class="chapter" data-level="4" data-path="progress-notes.html"><a href="progress-notes.html"><i class="fa fa-check"></i><b>4</b> Progress Notes</a></li>
<li class="chapter" data-level="5" data-path="discharges.html"><a href="discharges.html"><i class="fa fa-check"></i><b>5</b> Discharges</a></li>
<li class="part"><span><b>Postoperative Care</b></span></li>
<li class="chapter" data-level="6" data-path="colectomy---hill.html"><a href="colectomy---hill.html"><i class="fa fa-check"></i><b>6</b> Colectomy - Hill</a></li>
<li class="chapter" data-level="7" data-path="lar-ileostomy.html"><a href="lar-ileostomy.html"><i class="fa fa-check"></i><b>7</b> LAR + Ileostomy</a></li>
<li class="chapter" data-level="8" data-path="abdominoperineal-resection.html"><a href="abdominoperineal-resection.html"><i class="fa fa-check"></i><b>8</b> Abdominoperineal Resection</a></li>
<li class="chapter" data-level="9" data-path="esophagectomy-postop.html"><a href="esophagectomy-postop.html"><i class="fa fa-check"></i><b>9</b> Esophagectomy Postop</a></li>
<li class="chapter" data-level="10" data-path="esophagectomy-ward.html"><a href="esophagectomy-ward.html"><i class="fa fa-check"></i><b>10</b> Esophagectomy Ward</a>
<ul>
<li class="chapter" data-level="10.1" data-path="esophagectomy-ward.html"><a href="esophagectomy-ward.html#anti-hypertensives"><i class="fa fa-check"></i><b>10.1</b> Anti-Hypertensives</a></li>
<li class="chapter" data-level="10.2" data-path="esophagectomy-ward.html"><a href="esophagectomy-ward.html#chest-tubes"><i class="fa fa-check"></i><b>10.2</b> Chest tubes</a></li>
<li class="chapter" data-level="10.3" data-path="esophagectomy-ward.html"><a href="esophagectomy-ward.html#gi-medicines"><i class="fa fa-check"></i><b>10.3</b> GI Medicines</a></li>
<li class="chapter" data-level="10.4" data-path="esophagectomy-ward.html"><a href="esophagectomy-ward.html#leak_evaluation"><i class="fa fa-check"></i><b>10.4</b> Evaluation for leak</a>
<ul>
<li class="chapter" data-level="10.4.1" data-path="esophagectomy-ward.html"><a href="esophagectomy-ward.html#drain_amylase"><i class="fa fa-check"></i><b>10.4.1</b> Drain Amylase</a></li>
<li class="chapter" data-level="10.4.2" data-path="esophagectomy-ward.html"><a href="esophagectomy-ward.html#ct_esophagram"><i class="fa fa-check"></i><b>10.4.2</b> CT esophagram</a></li>
</ul></li>
<li class="chapter" data-level="10.5" data-path="esophagectomy-ward.html"><a href="esophagectomy-ward.html#anastomotic-leak-treatment"><i class="fa fa-check"></i><b>10.5</b> Anastomotic Leak Treatment</a></li>
<li class="chapter" data-level="10.6" data-path="esophagectomy-ward.html"><a href="esophagectomy-ward.html#jejunostomy_diabetes"><i class="fa fa-check"></i><b>10.6</b> Jejunostomy + Diabetes</a></li>
</ul></li>
<li class="part"><span><b>Hill OR</b></span></li>
<li class="chapter" data-level="11" data-path="colorectal-cases---hill.html"><a href="colorectal-cases---hill.html"><i class="fa fa-check"></i><b>11</b> Colorectal Cases - Hill</a></li>
<li class="chapter" data-level="12" data-path="student-emr-notes-policy.html"><a href="student-emr-notes-policy.html"><i class="fa fa-check"></i><b>12</b> Student EMR Notes Policy</a></li>
<li class="part"><span><b>Salo OR</b></span></li>
<li class="chapter" data-level="13" data-path="cv_port_salo.html"><a href="cv_port_salo.html"><i class="fa fa-check"></i><b>13</b> Central Venous Port (IJ)</a></li>
<li class="chapter" data-level="14" data-path="lap-jejunostomy.html"><a href="lap-jejunostomy.html"><i class="fa fa-check"></i><b>14</b> Lap Jejunostomy</a></li>
<li class="chapter" data-level="15" data-path="lap_gastrostomy_salo.html"><a href="lap_gastrostomy_salo.html"><i class="fa fa-check"></i><b>15</b> Lap Gastrostomy</a></li>
<li class="chapter" data-level="16" data-path="esophagectomy-one-stage.html"><a href="esophagectomy-one-stage.html"><i class="fa fa-check"></i><b>16</b> Esophagectomy One Stage</a></li>
<li class="part"><span><b>Esophageal Cancer</b></span></li>
<li class="chapter" data-level="17" data-path="EsoIntro.html"><a href="EsoIntro.html"><i class="fa fa-check"></i><b>17</b> Esophageal Overview</a></li>
<li class="chapter" data-level="18" data-path="staging.html"><a href="staging.html"><i class="fa fa-check"></i><b>18</b> Staging</a></li>
<li class="chapter" data-level="19" data-path="superficial.html"><a href="superficial.html"><i class="fa fa-check"></i><b>19</b> Superficial EsoCa</a>
<ul>
<li class="chapter" data-level="19.1" data-path="superficial.html"><a href="superficial.html#emr"><i class="fa fa-check"></i><b>19.1</b> Endscopic Mucosal Resection (EMR)</a></li>
</ul></li>
<li class="chapter" data-level="20" data-path="localized.html"><a href="localized.html"><i class="fa fa-check"></i><b>20</b> Localized EsoCa</a>
<ul>
<li class="chapter" data-level="20.1" data-path="localized.html"><a href="localized.html#t1b-tumors"><i class="fa fa-check"></i><b>20.1</b> T1b Tumors</a></li>
<li class="chapter" data-level="20.2" data-path="localized.html"><a href="localized.html#t2n0-tumors"><i class="fa fa-check"></i><b>20.2</b> T2N0 Tumors</a></li>
<li class="chapter" data-level="20.3" data-path="localized.html"><a href="localized.html#staging-of-t2n0-tumors"><i class="fa fa-check"></i><b>20.3</b> Staging of T2N0 Tumors</a></li>
</ul></li>
<li class="chapter" data-level="21" data-path="locally_advanced.html"><a href="locally_advanced.html"><i class="fa fa-check"></i><b>21</b> Locally Advanced EsoCa</a>
<ul>
<li class="chapter" data-level="21.1" data-path="locally_advanced.html"><a href="locally_advanced.html#trimodality"><i class="fa fa-check"></i><b>21.1</b> Trimodality Therapy</a>
<ul>
<li class="chapter" data-level="21.1.1" data-path="locally_advanced.html"><a href="locally_advanced.html#neoadjuvant-chemort-for-scca"><i class="fa fa-check"></i><b>21.1.1</b> Neoadjuvant chemoRT for SCCA</a></li>
<li class="chapter" data-level="21.1.2" data-path="locally_advanced.html"><a href="locally_advanced.html#neoadjuvant-chemotheraphy-followed-by-surgery"><i class="fa fa-check"></i><b>21.1.2</b> Neoadjuvant chemotheraphy followed by surgery</a></li>
</ul></li>
<li class="chapter" data-level="21.2" data-path="locally_advanced.html"><a href="locally_advanced.html#ge-junction"><i class="fa fa-check"></i><b>21.2</b> GE Junction</a></li>
<li class="chapter" data-level="21.3" data-path="locally_advanced.html"><a href="locally_advanced.html#induction-chemotherapy-followed-by-chemort"><i class="fa fa-check"></i><b>21.3</b> Induction chemotherapy followed by chemoRT</a></li>
<li class="chapter" data-level="21.4" data-path="locally_advanced.html"><a href="locally_advanced.html#postoperative-chemoradiation"><i class="fa fa-check"></i><b>21.4</b> Postoperative chemoradiation</a></li>
</ul></li>
<li class="chapter" data-level="22" data-path="eso_dcrt.html"><a href="eso_dcrt.html"><i class="fa fa-check"></i><b>22</b> Chemoradiation</a>
<ul>
<li class="chapter" data-level="22.1" data-path="eso_dcrt.html"><a href="eso_dcrt.html#phase-ii-studies"><i class="fa fa-check"></i><b>22.1</b> Phase II Studies</a></li>
<li class="chapter" data-level="22.2" data-path="eso_dcrt.html"><a href="eso_dcrt.html#chemort-vs-trimodality-therapy"><i class="fa fa-check"></i><b>22.2</b> ChemoRT vs Trimodality therapy</a></li>
</ul></li>
<li class="chapter" data-level="23" data-path="radiation.html"><a href="radiation.html"><i class="fa fa-check"></i><b>23</b> Radiation</a></li>
<li class="chapter" data-level="24" data-path="esophagectomy.html"><a href="esophagectomy.html"><i class="fa fa-check"></i><b>24</b> Esophagectomy</a>
<ul>
<li class="chapter" data-level="24.0.1" data-path="esophagectomy.html"><a href="esophagectomy.html#preoperative-evaluation"><i class="fa fa-check"></i><b>24.0.1</b> Preoperative Evaluation</a></li>
<li class="chapter" data-level="24.1" data-path="esophagectomy.html"><a href="esophagectomy.html#minimally-invasive-esophagectomy"><i class="fa fa-check"></i><b>24.1</b> Minimally-invasive Esophagectomy</a></li>
<li class="chapter" data-level="24.2" data-path="esophagectomy.html"><a href="esophagectomy.html#transthoracic"><i class="fa fa-check"></i><b>24.2</b> Transthoracic</a></li>
<li class="chapter" data-level="24.3" data-path="esophagectomy.html"><a href="esophagectomy.html#transhiatal"><i class="fa fa-check"></i><b>24.3</b> Transhiatal</a></li>
<li class="chapter" data-level="24.4" data-path="esophagectomy.html"><a href="esophagectomy.html#three-hole"><i class="fa fa-check"></i><b>24.4</b> Three-hole</a></li>
<li class="chapter" data-level="24.5" data-path="esophagectomy.html"><a href="esophagectomy.html#extended-lymphadenectomy"><i class="fa fa-check"></i><b>24.5</b> Extended lymphadenectomy</a></li>
<li class="chapter" data-level="24.6" data-path="esophagectomy.html"><a href="esophagectomy.html#salvage-esophagectomy"><i class="fa fa-check"></i><b>24.6</b> Salvage esophagectomy</a></li>
</ul></li>
<li class="chapter" data-level="25" data-path="eso_metastatic.html"><a href="eso_metastatic.html"><i class="fa fa-check"></i><b>25</b> Metastatic EsoCa</a>
<ul>
<li class="chapter" data-level="25.1" data-path="eso_metastatic.html"><a href="eso_metastatic.html#palliative-radiation"><i class="fa fa-check"></i><b>25.1</b> Palliative radiation</a></li>
<li class="chapter" data-level="25.2" data-path="eso_metastatic.html"><a href="eso_metastatic.html#chemoradiation-vs-chemotherapy-in-stage-iv"><i class="fa fa-check"></i><b>25.2</b> Chemoradiation vs chemotherapy in Stage IV</a></li>
<li class="chapter" data-level="25.3" data-path="eso_metastatic.html"><a href="eso_metastatic.html#stents-for-malignant-disease"><i class="fa fa-check"></i><b>25.3</b> Stents for malignant disease</a></li>
</ul></li>
<li class="chapter" data-level="26" data-path="eso_survivorship.html"><a href="eso_survivorship.html"><i class="fa fa-check"></i><b>26</b> Survivorship</a>
<ul>
<li class="chapter" data-level="26.1" data-path="eso_survivorship.html"><a href="eso_survivorship.html#nutritional-consequences"><i class="fa fa-check"></i><b>26.1</b> Nutritional consequences</a></li>
<li class="chapter" data-level="26.2" data-path="eso_survivorship.html"><a href="eso_survivorship.html#cardiac-toxicity-of-radiation"><i class="fa fa-check"></i><b>26.2</b> Cardiac toxicity of radiation</a></li>
<li class="chapter" data-level="26.3" data-path="eso_survivorship.html"><a href="eso_survivorship.html#eso_surveillance"><i class="fa fa-check"></i><b>26.3</b> Surveillance</a></li>
</ul></li>
<li class="part"><span><b>Gastric Cancer</b></span></li>
<li class="chapter" data-level="27" data-path="gastric-overview.html"><a href="gastric-overview.html"><i class="fa fa-check"></i><b>27</b> Gastric Overview</a>
<ul>
<li class="chapter" data-level="27.1" data-path="gastric-overview.html"><a href="gastric-overview.html#ge-junction-classification"><i class="fa fa-check"></i><b>27.1</b> GE junction classification</a></li>
</ul></li>
<li class="chapter" data-level="28" data-path="gast_superficial.html"><a href="gast_superficial.html"><i class="fa fa-check"></i><b>28</b> Superficial Gastric</a></li>
<li class="chapter" data-level="29" data-path="locally-advanced-gastric.html"><a href="locally-advanced-gastric.html"><i class="fa fa-check"></i><b>29</b> Locally-Advanced Gastric</a>
<ul>
<li class="chapter" data-level="29.1" data-path="locally-advanced-gastric.html"><a href="locally-advanced-gastric.html#preoperative-chemotherapy"><i class="fa fa-check"></i><b>29.1</b> Preoperative Chemotherapy</a></li>
<li class="chapter" data-level="29.2" data-path="locally-advanced-gastric.html"><a href="locally-advanced-gastric.html#postoperative-chemotherapy"><i class="fa fa-check"></i><b>29.2</b> Postoperative chemotherapy</a></li>
<li class="chapter" data-level="29.3" data-path="locally-advanced-gastric.html"><a href="locally-advanced-gastric.html#postoperative-chemoradiation-1"><i class="fa fa-check"></i><b>29.3</b> Postoperative chemoradiation</a></li>
<li class="chapter" data-level="29.4" data-path="locally-advanced-gastric.html"><a href="locally-advanced-gastric.html#preoperative-chemoradiation"><i class="fa fa-check"></i><b>29.4</b> Preoperative chemoradiation</a></li>
</ul></li>
<li class="chapter" data-level="30" data-path="gastric-carcinoids.html"><a href="gastric-carcinoids.html"><i class="fa fa-check"></i><b>30</b> Gastric Carcinoids</a></li>
<li class="chapter" data-level="31" data-path="gi-stromal-tumors.html"><a href="gi-stromal-tumors.html"><i class="fa fa-check"></i><b>31</b> GI Stromal Tumors</a></li>
<li class="part"><span><b>Colorectal Cancer</b></span></li>
<li class="chapter" data-level="32" data-path="colon-cancer-staging.html"><a href="colon-cancer-staging.html"><i class="fa fa-check"></i><b>32</b> Colon Cancer Staging</a>
<ul>
<li class="chapter" data-level="32.1" data-path="colon-cancer-staging.html"><a href="colon-cancer-staging.html#cea-level"><i class="fa fa-check"></i><b>32.1</b> CEA level</a></li>
<li class="chapter" data-level="32.2" data-path="colon-cancer-staging.html"><a href="colon-cancer-staging.html#ct-scan"><i class="fa fa-check"></i><b>32.2</b> CT Scan</a></li>
<li class="chapter" data-level="32.3" data-path="colon-cancer-staging.html"><a href="colon-cancer-staging.html#pet-scan"><i class="fa fa-check"></i><b>32.3</b> PET scan</a>
<ul>
<li class="chapter" data-level="32.3.1" data-path="colon-cancer-staging.html"><a href="colon-cancer-staging.html#indications-for-pet-in-colorectal-cancer"><i class="fa fa-check"></i><b>32.3.1</b> Indications for PET in colorectal cancer:</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="33" data-path="colectomy.html"><a href="colectomy.html"><i class="fa fa-check"></i><b>33</b> Colectomy</a>
<ul>
<li class="chapter" data-level="33.1" data-path="colectomy.html"><a href="colectomy.html#extended-node-dissection"><i class="fa fa-check"></i><b>33.1</b> Extended Node dissection</a></li>
</ul></li>
<li class="chapter" data-level="34" data-path="chemotherapy.html"><a href="chemotherapy.html"><i class="fa fa-check"></i><b>34</b> Chemotherapy</a>
<ul>
<li class="chapter" data-level="34.1" data-path="chemotherapy.html"><a href="chemotherapy.html#neoadjuvant-chemotherapy"><i class="fa fa-check"></i><b>34.1</b> Neoadjuvant Chemotherapy</a></li>
</ul></li>
<li class="chapter" data-level="35" data-path="rectal-cancer.html"><a href="rectal-cancer.html"><i class="fa fa-check"></i><b>35</b> Rectal Cancer</a></li>
<li class="part"><span><b>Sarcoma</b></span></li>
<li class="chapter" data-level="36" data-path="retroperitoneal.html"><a href="retroperitoneal.html"><i class="fa fa-check"></i><b>36</b> Retroperitoneal</a></li>
<li class="chapter" data-level="" data-path="references.html"><a href="references.html"><i class="fa fa-check"></i>References</a></li>
<li class="divider"></li>
<li><a href="mailto:jonathan.salo@atriumhealth.org">Feedback and Updates</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">GI Surgical Oncology</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="esophagectomy-ward" class="section level1" number="10">
<h1><span class="header-section-number">10</span> Esophagectomy Ward</h1>
<p><strong>Ward Care</strong></p>
<p>Once stable, patients are transferred to 6T. If a 6T bed is not available, please notify Dr Salo. Historically, over 95% of patients are transferred to 6T after leaving the ICU.</p>
<div id="anti-hypertensives" class="section level2" number="10.1">
<h2><span class="header-section-number">10.1</span> Anti-Hypertensives</h2>
<p>Patients are transitioned to enteral metoprolol once they are transferred to the ward. Patients on IV metoprolol at 2.5mg IV q6 hours are started on 25mg enteral bid, while patients receiving 5mg IV q6 hours are started on 50mg bid. For patients who are not taking medicines by mouth, liquid metoprolol can be ordered while an inpatient. (Liquid metoprolol is not available as a home medicine.)</p>
<p>Home anti-hypertensives are usually held in order to allow beta-blockade. Patients who have elevated blood pressures once they are adequately beta-blocked (eg HR 60-70) are usually restarted on their home anti-hypertensives. <em>Home anti-hypertensives are not routinely restarted postoperatively</em>. Home antihypertensives are restarted on a selective basis</p>
</div>
<div id="chest-tubes" class="section level2" number="10.2">
<h2><span class="header-section-number">10.2</span> Chest tubes</h2>
<p>Chest tubes generally consist of a 28Fr Blake drain placed into the right chest. This is placed to water seal when output is less than 200mL/day and there is no leak visible in the Pleurevac container. Chest tubes are usually removed once output is less than 150mL/day and drainage is clear without evidence of chyle (milky appearance). A chest x-ray is obtained after removing a chest tube to look for a pneumothorax.</p>
</div>
<div id="gi-medicines" class="section level2" number="10.3">
<h2><span class="header-section-number">10.3</span> GI Medicines</h2>
<p>All patients receive pantoprazole 40mg IV daily and metoclopramide 5-10mg IV q 6hrs. This is later switched to enteric PPI and reglan. For patients &lt;age 75, remeron is added as 15mg enteral qhs.</p>
</div>
<div id="leak_evaluation" class="section level2" number="10.4">
<h2><span class="header-section-number">10.4</span> Evaluation for leak</h2>
<p>Experience suggests that the median time to the diagnosis of leak is 7 day after surgery. Currently the risk of anastomotic leak at CMC after transthoracic esophagectomy is 2%. The most sensitive test for the diagnosis of leak is CT esophagram (see below). Based upon institutional experience, patients are divided into low risk of leak vs high risk for leak based upon drain amylase level and white blood cell count. Patients with a normal drain amylase (400IU/ml) between postoperative day 4 and day 7 AND white blood cell count less than 12 are considered low risk. Patients with either an elevated drain amylase or WBC greater than 12 are evaluated with CT esophagram. In a group of 100 patients, several were found to have elevated drain amylase in the first four days (up to 2000Iu/ml) which subsequently declined, and no evidence of leak was found</p>
<div id="drain_amylase" class="section level3" number="10.4.1">
<h3><span class="header-section-number">10.4.1</span> Drain Amylase</h3>
<p>JP2 is placed into the right pleura, passes through the hiatus, and is brought out through a trocar site in the medial left upper quadrant. Drain amylase from JP2 is tested beginning on postoperative day #4 until discharge or postoperative day #9. JP2 is generally removed prior to patient discharge. JP1 is placed in the left pleura and is generally not tested for amylase.</p>
</div>
<div id="ct_esophagram" class="section level3" number="10.4.2">
<h3><span class="header-section-number">10.4.2</span> CT esophagram</h3>
<p>This is the most sensitive study for the detection of anastomotic leak. In order to obtain sufficient sensitivity, it requires a pre-contrast scan and the administration of contrast into the esophagus. The need for a pre-contrast scan means that the presence of remnant barium in the esophagus (from a Modified Barium Swallow) makes it more difficult to interpret the scan and should be avoided. Awake patients can drink the contrast. Patients with an NG tube present at the time of the study generally will have contrast administered through their NG tube. Almost all esophagectomy patients will have a Covidien silicone Salem Sump 18Fr tube in place. This has four marks on the tube at 45, 55, 65, and 75cm. The tube is typically positioned with the 4th mark at the nares, which means that the tip is 45cm from the nares and is usually within the gastric conduit AND below the anastomosis. The NG tube also contains side holes which extend 8.5cm above the tip of the tube. The optimal study is done with the NG tube withdrawn so that there are two side-holes above the anastomosis, which means that the tip is approximately 6cm below the anastomosis. A scout CT will be performed, and the radiologist will determine how far back the NG tube needs to be withdrawn. This is communicated to the CT technician, who asks the nurse (or physician) to withdraw the tube the calculated amount (making a note of the starting position of the tube relative to the four marks). This should keep the tip below the level of the anastomosis, so that after the CT scan, the NG tube can be (blindly) advanced back to its original position (at approximately 45cm from the nares).</p>
<p>Patients who clinically deteriorate prior to post-operative day 7 in whom there is high suspicion for a leak (fevers, pleural effusion on chest X-ray, elevated JP amylase, respiratory failure) will undergo a CT esophagram earlier than post-operative day 7.</p>
</div>
</div>
<div id="anastomotic-leak-treatment" class="section level2" number="10.5">
<h2><span class="header-section-number">10.5</span> Anastomotic Leak Treatment</h2>
<p>If a patient is demonstrated to have a leak, they are made NPO AND will have any pleural effusion treated with a pigtail catheter. Conservative management will generally be successful for most patients with leaks provided 1) there is no evidence of conduit necrosis 2) nutrition is optimized and 3) empyema is treated. Patients with leaks may even need a decortication, which emphasizes the importance of CT scan in the sick post-operative esophagectomy patient, so that an empyema can be diagnosed and treated. Patients with leaks who show signs of systemic illness may need to be considered for an intraluminal stent. Patients who are profoundly ill need to be evaluated for gastric necrosis with upper endoscopy.</p>
<p><strong>Nutrition</strong></p>
<p>All esophagectomy patients receive a feeding jejunostomy at the time of operation. In the immediate post-operative period, patients receive Osmolite 1.5 starting the day of surgery once they are off pressors. Tube feeds are started at 20mL/hour until flatus and then advanced at 10mL per hour every 8 hours, up to a goal of 60mL per hour (x24 hours). Patients who are on tube feeds prior to surgery are generally restarted on their home tube feed formula.</p>
<p>Patients who do not tolerate Osmolite are switched to Vital 1.5, which is pre-hydrolyzed. In order to allow enough time for switching of tube feedings, patients are generally switched from Vital to their home tube feeding formula 3-4 days prior to discharge. This is typically done when they are transferred out of the ICU.</p>
<p>Obese patients (BMI&gt;30) are started on Promote at 20mL/hour and increased to a goal of 60mL/hour. Promote contains a more protein relative to carbohydrdates. An alternative is Vital High Protein, which is similar to Promote but using hydrolyzed proteins.</p>
<p>Diarrhea in patients on tube feeds (especially nocturnal diarrhea) needs to be addressed. Despite STICU guidelines for nutrition in trauma patients, diarrhea (especially night-time diarrhea) is justification for alteration in tube feeds. See Diarrhea and Jejunstomy Feeding</p>
<p><em>Diabetic Patients</em></p>
<p>Patients on tube feeds are typically started on continuous (around-the-clock) tube feedings, and subsequently changed to a nocturnal regimen (typically 6pm to 10am). See <a href="esophagectomy-ward.html#jejunostomy_diabetes">Jejunostomy Feeds in Diabetic Patients</a></p>
<p><em>‘Free Water’</em></p>
<p>In addition to tube feeds, most patients will receive ‘free’ water flushes through the jejunostomy. This is typically done as 240mL four times per day (for a total of 32oz)</p>
<p><em>Nasogastric Tubes</em></p>
<p>A silicone nasogastric tube (Covidien Salem Sump) is placed in all patients during surgery and the position confirmed by ultrasound intraoperatively. Tubes are positioned so that all 4 dots are outside. Gastric emptying is evaluated with upper GI prior to NG tube removal. Once extubated, upper GI is typically performed on the 2nd through 4th postoperative day. Conversely, patients who are intubated will keep their nasogastric tube until extubated.</p>
<p><em>Drains</em></p>
<ul>
<li>JP1: 19Fr Blake drain in left pleura. The exit site the most lateral drain and is secured with a blue suture</li>
<li>JP2: 19Fr Blake drain in right pleura. The exit site is medial to JP1 and is secured with a black suture</li>
<li>JP3: 19 Fr Blake drain in abdomen. If used, the exit site is most medial and is secured with a blue suture</li>
<li>JP4: 15Fr Blake drain in neck (for cervial incision)</li>
<li>JP5: 15Fr Blake drain in subcutaneous tissue of incision</li>
</ul>
<p><em>Evaluation for Anastomotic leak</em></p>
<p>Drain amylase is an inexpensive, specific, and relatively sensitive test for anastomotic leak. Fluid from JP2 (right chest) is sent for “Body Fluid Amylase” starting on postoperative day #4 and continued until postoperative day 9. Drain amylase over 400IU/ml is considered positive and prompts a CT esophagram for confirmation. See also Evaluation for Anastomotic Leak</p>
<p><strong>Renal</strong>
Total fluids (IV + tube feeds) are generally run at 75mL/hour. Foley catheter is removed on the first or second day after surgery. Some patients will need diuresis on the 3rd or 4th postoperative day</p>
<p><strong>Heme</strong>
All patients require VTE prophylaxis with Lovenox or heparin SQ.</p>
<p>Preoperative anti-platelet agents are started on the first (aspirin) or second (Plavix) postoperative day if there is no excessive bleeding from the chest tube or JP drains. Patients on preoperative anticoagulation are transitioned to therapeutic Lovenox on the second postoperative day if no signs of bleeding.</p>
<p><strong>ID</strong>
Prophylactic Cefazolin and Flagyl are administered for 24 hours and stopped</p>
<p>Discharge Medicines
Patients after esophagectomy typically go home with the following medicines:</p>
<p>Proton pump inhibitors (will continue for 2 years)
Oxycodone elixir via feeding tube. Current STOP guidelines dictate that patients receive no more than a 7 day supply of opiods at discharage
Reglan 10mg po qid (will stop at 6 weeks post-op)
Remeron 15mg qhs (will continue for 3 months post-op)
Tylenol 1000mg q6 hours as elixir (pediatric form)
Gabapentin 300mg as liquid tid x 14 days
Metoprolol if started postoperatively (most patients). If not on beta blockers preoperatively, this will be cut in half at the first visit and stopped at the second postoperative visit. It is important to limit the use of medicines via jejunostomy in order to lower the risk of clogging the feeding tube. While liquid metoprolol is available for inpatients, it is not available from outpatient pharmacies.</p>

</div>
<div id="jejunostomy_diabetes" class="section level2" number="10.6">
<h2><span class="header-section-number">10.6</span> Jejunostomy + Diabetes</h2>
<p><strong>Inpt – Jejunostomy ~ Diabetes</strong></p>
<p>Patients on tube feeds are typically started on continuous (around-the-clock) tube feedings, and subsequently changed to a nocturnal regimen (typically 6pm to 10am). The diabetic management for these patients differs depending upon their tube feeding regimen:</p>
<p><strong>Diabetics on Continuous Tube Feeds.</strong></p>
<p>Non-insulin diabetic patients are generally initially given Osmolite 1.5 as it provides higher caloric density and does not contain fiber, which tends to clog the feeding tubes. Diabetic patients requiring insulin can be initially trialed on Osmolite 1.5 but are changed to Promote or Glucerna 1.5 if their blood sugars prove difficult to control (as evidence by either the need for EndoTool or requiring a q6 hour regimen of insulin N + insulin R).</p>
<p>Diabetic patients who need insulin while receiving tube feedings are typically treated initially with continuous tube feedings and around-the-clock insulin. Patients with large insulin requirements may need hourly intravenous insulin (with dosages calculated via EndoTool). Once their insulin requirements are stabilized, they are transitioned to a q6 hour regimen consisting of N and R insulin, typically twice as many units of N insulin as R (for instance, 6Units of N + 3 Units of R insulin every six hours). Patients who require EndoTool or a q6hr regimen need an endocrinology consultation with Dr Kelli Dunn to assist in diabetic management.</p>
<p><strong>Diabetics on Nocturnal Tube Feeds</strong></p>
<p>Most patients are transitioned from continuous tube feeds to nocturnal prior to discharge. Diabetic patients on nocturnal tube feedings typically receive tube feeding from 6pm to 10am and receive insulin at initiation of tube feeds (6pm) and again at 6 hours later (midnight). A typical regimen might be 18U of 70/30 at 1800 and 18U of 70/30 at MN. An alternative might be 12U NPH + 6U Regular at 1800 and 16U NPH and 8U Regular insulin at MN. Because it can take several days to determine the correct insulin regimen, diabetic patients receiving jejunostomy feedings are cycled as early in their hospital course as possible to avoid delaying discharge for blood sugar management.</p>
<p>Diabetic patients receiving insulin will need careful coordination of tube feeding and insulin administration when they are being transitioned from continuous to nocturnal tube feeds. Patients on continuous tube feeds may receive insulin on a q6 hour schedule, while those receiving nocturnal tube feeds receive insulin at 1800 and MN. When patients on continuous tube feeds are transitioned, the tube feeds are stopped at 10am, to be restarted at 6pm that evening. It is critical that as soon as the tube feeds are stopped at 10am, that the q6 hour insulin as stopped as well.</p>
<p>In either case it is critical that if tube feedings are stopped, standing insulin administration (either q6 hour OR 1800 and MN) be stopped as well. In these cases, sliding scale insulin is generally continued.</p>
<table>
<thead>
<tr class="header">
<th>Day</th>
<th>Time</th>
<th>Tube Feeds</th>
<th>Insulin</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>SUN</td>
<td>MN</td>
<td>60mL/hr</td>
<td>8N+4R</td>
</tr>
<tr class="even">
<td>Mon</td>
<td>6am</td>
<td>60mL/hr</td>
<td>8N+R</td>
</tr>
<tr class="odd">
<td>Mon</td>
<td>Noon</td>
<td>Stop</td>
<td>None</td>
</tr>
<tr class="even">
<td>Mon</td>
<td>6pm</td>
<td>75mL/hr</td>
<td>16N + 8R</td>
</tr>
<tr class="odd">
<td>Mon</td>
<td>MN</td>
<td>75mL/hr</td>
<td>16N+ 8R</td>
</tr>
<tr class="even">
<td>Tues</td>
<td>10am</td>
<td>Stop</td>
<td>None</td>
</tr>
<tr class="odd">
<td>Tues</td>
<td>6pm</td>
<td>75mL/hr</td>
<td>16N+ 8R</td>
</tr>
<tr class="even">
<td>Tues</td>
<td>MN</td>
<td>75mL/hr</td>
<td>16N+ 8R</td>
</tr>
<tr class="odd">
<td>Weds</td>
<td>10am</td>
<td>Stop</td>
<td>None</td>
</tr>
</tbody>
</table>
<p>In this example, the patient was receiving 8N + 4R every 6 hours, so total insulin units per day is (8+4) x 4 = 48units. Because the carbohydrate load of 60mL/hour x 24 is roughly equivalent to 75mL/hour x 16 hours, the total insulin administered is roughly the same. When converted to nocturnal dosing, the patient now received 16+8 = 24 units twice (6pm and MN) = 48U. In practice, it may be wiser to begin by adjusting the dose down a little, to perhaps 14U N and 7U R for the first night.</p>
<p><strong>Weaning Tube Feeds</strong></p>
<p>As outpatients begin eating more orally, their tube feeds are reduced.</p>
<p>Weaning from 5 cans to 4 cans: Easiest method is to maintain the same schedule (16 hours) and reduce insulin dosage by 20%. For instance, the above patient who is on 5 cans at 75mL/hour x 16 hours is receiving 16N + 8R at start of tube feeds and 6 hours later. This patient could be weaned by reducing rate form 75mL/hour x 16 hours to 60mL/hour x 16 hours and reducing insulin to 12N + 6R at the start of tube feeds AND another dose of 12N + 6R after 6 hours.</p>
<p>Weaning from 4 cans to 3 cans: One option is to decrease the duration of tube feeds from 16 hours to 12 hours, while maintaining rate of 60mL/hour. In this case, the insulin dosage could be kept the same at the start of tube feeds, BUT the dose 6 hours after the start of tube feeds could be omitted.</p>
<p>Once patients are on 3 cans per night, further weaning can be accomplished by skipping tube feeds (and insulin) every other night in a “tube feed holiday.” This allows an evening of interrupted sleep and can tend to increase the appetite the morning after tube feeds are held.</p>

</div>
</div>



            </section>

          </div>
        </div>
      </div>
<a href="esophagectomy-postop.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="colorectal-cases---hill.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/jcsalo/gi_surgonc/edit/main/141-esophagectomy_ward.Rmd",
"text": "Edit"
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": ["gi_surgonc.pdf", "gi_surgonc.epub"],
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "section",
"scroll_highlight": true,
"search": true,
"sharing": false
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
